Twist Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Twist Bioscience 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TWST

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. 

CEO
Emily Marine Leproust
CEOEmily Marine Leproust
Employees
923
Employees923
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
923
Employees923

TWST Key Statistics

Market cap
1.89B
Market cap1.89B
Price-Earnings ratio
-21.57
Price-Earnings ratio-21.57
Dividend yield
Dividend yield
Average volume
1.33M
Average volume1.33M
High today
$31.92
High today$31.92
Low today
$30.75
Low today$30.75
Open price
$31.12
Open price$31.12
Volume
413.18K
Volume413.18K
52 Week high
$55.33
52 Week high$55.33
52 Week low
$24.07
52 Week low$24.07

Stock Snapshot

Twist Bioscience(TWST) stock is priced at $31.30, giving the company a market capitalization of 1.89B. It carries a P/E multiple of -21.57.

During the trading session on 2025-11-12, Twist Bioscience(TWST) shares reached a daily high of $31.92 and a low of $30.75. At a current price of $31.30, the stock is +1.8% higher than the low and still -1.9% under the high.

Trading volume for Twist Bioscience(TWST) stock has reached 413.18K, versus its average volume of 1.33M.

Over the past 52 weeks, Twist Bioscience(TWST) stock has traded between a high of $55.33 and a low of $24.07.

Over the past 52 weeks, Twist Bioscience(TWST) stock has traded between a high of $55.33 and a low of $24.07.

TWST News

Nasdaq 4h
Ovid Therapeutics Reports Q3 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0...

Ovid Therapeutics Reports Q3 Loss, Lags Revenue Estimates
Simply Wall St 6d
Will a New Sequencing Collaboration Redefine Twist Bioscience's Innovation and Market Expansion Narrative?

In recent days, Stephens initiated coverage on Twist Bioscience, highlighting the company's proprietary silicon chip technology and operational strengths, while...

Will a New Sequencing Collaboration Redefine Twist Bioscience's Innovation and Market Expansion Narrative?

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own TWST. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.